Nexavar fails recurrence target

Share this article:
Nexavar fails recurrence target
Nexavar fails recurrence target

Phase-III tests using oncology drug Nexavar as an adjuvant therapy for liver cancer failed to meet a recurrence-free survival target. Partners Bayer and Amgen's Onyx division announced the results Tuesday, and said they will detail results of the STORM clinical trial at a scientific conference.

Amgen funds 50% of Nexavar R&D costs and co-promotes the drug with Bayer in the US through its own sales force and medical science liaisons.

The 1,100 patient trial assessed cancer patients who appeared cancer-free after surgical resection or ablation. These patients received 400mg of sorafenib or a placebo for four years, or until the cancer returned. The drug was one of Bayer's top-selling pharmaceuticals in 2013, earning $1 billion in 2013, behind contraceptive Yaz, which ranked fourth among last year's best sellers. While on Bayer's hit-list, higher US prices helped keep sales high, yet still slipped 2.7% compared to sales in 2012.

The drug's approved indications include advanced renal cell carcinoma (2005) and unresectable hepatocellular carcinoma (2007). The FDA approved Nexavar for locally recurrent or metastatic, progressive differentiated thyroid cancer refractory to iodine under priority review in November.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.